287 related articles for article (PubMed ID: 31509209)
1. US Food and Drug Administration Approvals of Drugs and Devices Based on Nonrandomized Clinical Trials: A Systematic Review and Meta-analysis.
Razavi M; Glasziou P; Klocksieben FA; Ioannidis JPA; Chalmers I; Djulbegovic B
JAMA Netw Open; 2019 Sep; 2(9):e1911111. PubMed ID: 31509209
[TBL] [Abstract][Full Text] [Related]
2. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.
Shepshelovich D; Tibau A; Goldvaser H; Ocana A; Seruga B; Amir E
Mayo Clin Proc; 2019 Jan; 94(1):74-83. PubMed ID: 30611457
[TBL] [Abstract][Full Text] [Related]
3. When are randomized trials unnecessary? A signal detection theory approach to approving new treatments based on non-randomized studies.
Djulbegovic B; Razavi M; Hozo I
J Eval Clin Pract; 2021 Aug; 27(4):735-742. PubMed ID: 33103322
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.
Hilal T; Sonbol MB; Prasad V
JAMA Oncol; 2019 Jun; 5(6):887-892. PubMed ID: 31046071
[TBL] [Abstract][Full Text] [Related]
5. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses.
Hart B; Lundh A; Bero L
BMJ; 2012 Jan; 344():d7202. PubMed ID: 22214754
[TBL] [Abstract][Full Text] [Related]
6. Postmarketing trials and pediatric device approvals.
Hwang TJ; Kesselheim AS; Bourgeois FT
Pediatrics; 2014 May; 133(5):e1197-202. PubMed ID: 24733871
[TBL] [Abstract][Full Text] [Related]
7. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
[TBL] [Abstract][Full Text] [Related]
8. Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease: A Systematic Review and Meta-analysis.
Martinkova J; Quevenco FC; Karcher H; Ferrari A; Sandset EC; Szoeke C; Hort J; Schmidt R; Chadha AS; Ferretti MT
JAMA Netw Open; 2021 Sep; 4(9):e2124124. PubMed ID: 34515784
[TBL] [Abstract][Full Text] [Related]
9. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
10. Design analysis indicates Potential overestimation of treatment effects in randomized controlled trials supporting Food and Drug Administration cancer drug approvals.
Lord EM; Weir IR; Trinquart L
J Clin Epidemiol; 2018 Nov; 103():1-9. PubMed ID: 30297036
[TBL] [Abstract][Full Text] [Related]
11. Control Groups in RCTs Supporting Approval of Drugs for Systemic Rheumatic Diseases, 2012-2022.
Liu Y; Xie Y; Qin Y; Xie Q; Chen X
JAMA Netw Open; 2023 Nov; 6(11):e2344767. PubMed ID: 37991756
[TBL] [Abstract][Full Text] [Related]
12. Contrasting clinical evidence for market authorisation of cardio-vascular devices in Europe and the USA: a systematic analysis of 10 devices based on Austrian pre-reimbursement assessments.
Wild C; Erdös J; Zechmeister I
BMC Cardiovasc Disord; 2014 Nov; 14():154. PubMed ID: 25366498
[TBL] [Abstract][Full Text] [Related]
13. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.
Tibau A; Molto C; Ocana A; Templeton AJ; Del Carpio LP; Del Paggio JC; Barnadas A; Booth CM; Amir E
J Natl Cancer Inst; 2018 May; 110(5):486-492. PubMed ID: 29244173
[TBL] [Abstract][Full Text] [Related]
14. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.
Jardim DL; Schwaederle M; Wei C; Lee JJ; Hong DS; Eggermont AM; Schilsky RL; Mendelsohn J; Lazar V; Kurzrock R
J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26378224
[TBL] [Abstract][Full Text] [Related]
15. Larger effect sizes in nonrandomized studies are associated with higher rates of EMA licensing approval.
Djulbegovic B; Glasziou P; Klocksieben FA; Reljic T; VanDenBergh M; Mhaskar R; Ioannidis JPA; Chalmers I
J Clin Epidemiol; 2018 Jun; 98():24-32. PubMed ID: 29432860
[TBL] [Abstract][Full Text] [Related]
16. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
[TBL] [Abstract][Full Text] [Related]
17. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
Darrow JJ; Avorn J; Kesselheim AS
JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
[TBL] [Abstract][Full Text] [Related]
18. Assessment of US Food and Drug Administration-Approved Digital Medical Devices for Just-in-Time Interventions: A Systematic Review.
Phi NTT; Oikonomidi T; Ravaud P; Tran VT
JAMA Intern Med; 2023 Aug; 183(8):858-869. PubMed ID: 37459057
[TBL] [Abstract][Full Text] [Related]
19. Agreements and Discrepancies between FDA Reports and Journal Papers on Biologic Agents Approved for Rheumatoid Arthritis: A Meta-Research Project.
Amarilyo G; Furst DE; Woo JM; Li W; Bliddal H; Christensen R; Tarp S
PLoS One; 2016; 11(1):e0147556. PubMed ID: 26808309
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.
Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS
JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
